What is the difference between PEG-MGF and Sermorelin?

PEG-MGF: PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols. Sermorelin: Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone). It was FDA-approved for pediatric GH deficiency diagnosis and is widely used off-label in anti-aging and performance medicine. It stimulates pulsatile GH release more physiologically than exogenous GH. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take PEG-MGF and Sermorelin together?

There is no specific, well-documented interaction rule for combining PEG-MGF and Sermorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, PEG-MGF or Sermorelin?

PEG-MGF is currently preclinical only and Sermorelin is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

PEG-MGF vs Sermorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

PEG-MGF

Preclinical only

PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols.

Full profile

Sermorelin

FDA-approved

Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone). It was FDA-approved for pediatric GH deficiency diagnosis and is widely used off-label in anti-aging and performance medicine. It stimulates pulsatile GH release more physiologically than exogenous GH.

Full profile

	PEG-MGF	Sermorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF	GHRH 1-29, GRF 1-29 NH2, Geref
Evidence	Preclinical only	FDA-approved
Dosing range	100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split)	100mcg–500mcg mcg, once daily (before sleep)
Administration	Subcutaneous injection (preferred for systemic distribution), Intramuscular injection	Subcutaneous injection
Key side effects	Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling	Injection site redness, Headache, Flushing, Dizziness
Cited sources	2 references	1 reference

Key differences

Evidence level differs: PEG-MGF is preclinical only, while Sermorelin is fda-approved.
Administration: PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection; Sermorelin — Subcutaneous injection.
Frequency: PEG-MGF is typically 2x weekly (Monday/Thursday or similar split); Sermorelin is once daily (before sleep).
Research depth: this profile cites 2 sources for PEG-MGF vs 1 for Sermorelin.

How each works

PEG-MGF

PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.

Sermorelin

Sermorelin works by binding pituitary GHRH receptors to stimulate GH secretion within the body's natural feedback loop. Unlike synthetic GH, it does not suppress endogenous production. Clinical studies show improved body composition, sleep quality, and IGF-1 levels in GH-deficient adults. Its short half-life (~10 min) means it requires daily dosing.

Read the full PEG-MGF profile Read the full Sermorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.